Description
CJC-1295 is a synthetic peptide that belongs to a class of compounds called growth hormone-releasing hormones (GHRHs). It binds to the GHRH receptor in the pituitary gland, which then triggers the release of growth hormones into the bloodstream.
It provides sustained stimulation of GH release over a longer period of time due to a longer half-life than other GHRHs. It has been investigated for its potential therapeutic use in conditions associated with GH deficiency, such as growth hormone deficiency, aging, and muscle wasting.
Some studies have shown that CJC-1295 can increase muscle mass and improve muscle strength, decrease body fat, and improve skin elasticity in older adults, including patients with cancer, COPD, and HIV/AIDS. Several clinical studies have also shown that CJC-1295 can increase levels of insulin-like growth factor-1 (IGF-1) and improve growth in children with growth hormone deficiency.
CJC -1295 without DAC (Drug Affinity Complex) is a shorter-acting form of the peptide that does not bind to serum albumin and is rapidly cleared.